NASDAQ$VRDN
Viridian Therapeutics Inc · Q2 2025 earnings
Q2 2025 earnings · · Before market open · Investor relations
Briefing
Viridian Therapeutics Inc reported a net loss of $100.7 million for the second quarter of 2025.
The company recorded collaboration revenue of $75 thousand and total operating expenses of $106.8 million, driven primarily by research and development costs of $86.6 million. This resulted in a net loss of $100.7 million or $1.00 per share on 81.6 million weighted average shares. Cash and cash equivalents stood at $117.3 million with short-term investments of $446.0 million at quarter end.
- Q2 2025 net loss totaled $100.7 million, reflecting increased R&D investment in clinical programs.
- Collaboration revenue remained minimal at $75 thousand from the Zenas BioPharma agreement.
- Research and development expenses rose to $86.6 million, supporting phase 3 trials for veligrotug and VRDN-003.
- Strong liquidity position maintained with $563.4 million in cash, cash equivalents, and short-term investments.
Headline financials
Revenue & EPS history
Viridian Therapeutics · Revenue · Quarterly
$75K
Revenue by segment
Viridian Therapeutics · $75K total across 1 segment · Q2 2025
- Collaboration revenue$75K—100.0%
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 19 quarterly earnings reports
+2.0%
Avg return
Earnings day
+0.7%
Avg return
5 days after
+1.6%
Avg return
30 days after
49%
23 / 47 earnings
Positive
+73.1%
Q2 2022
Best reaction
-23.7%
Q4 2019
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q2 2025 | — | — | — | |
| Q1 2026 | +33.5% | +18.2% | +17.9% | |
| Q4 2025 | +1.9% | +1.3% | -5.4% | |
| Q3 2025 | +8.3% | +22.6% | +42.0% | |
| Q1 2025 | +2.6% | +8.2% | +25.8% | |
| Q4 2024 | +1.6% | -0.1% | -5.6% | |
| Q3 2024 | -12.6% | -21.7% | -30.0% | |
| Q2 2024 | -2.5% | -4.5% | -8.5% | |
| Q1 2024 | -8.1% | -5.3% | -19.6% | |
| Q4 2023 | +4.7% | +3.2% | -9.1% | |
| Q3 2023 | +10.6% | +15.4% | +39.8% | |
| Q2 2023 | +8.6% | +10.6% | +5.6% | |
| Q1 2023 | -0.5% | -8.1% | -0.1% | |
| Q4 2022 | -11.0% | -12.4% | -22.8% | |
| Q3 2022 | +11.4% | +9.9% | +36.1% | |
| Q2 2022 | +73.1% | +60.1% | +56.1% | |
| Q1 2022 | +35.1% | +44.3% | +8.6% | |
| Q4 2021 | +2.2% | +1.4% | -5.3% | |
| Q3 2021 | +6.0% | +2.1% | +5.1% | |
| Q2 2021 | -15.5% | -18.4% | -12.4% | |
| Q1 2021 | -4.4% | -9.4% | -12.4% | |
| Q4 2020 | +3.4% | -4.9% | +5.5% | |
| Q3 2020 | -4.4% | -6.9% | +14.9% | |
| Q2 2020 | -4.4% | +1.8% | -21.1% | |
| Q1 2020 | +3.5% | +20.2% | +52.6% | |
| Q4 2019 | -23.7% | -37.1% | -31.0% | |
| Q3 2019 | -3.2% | -19.2% | -21.9% | |
| Q2 2019 | -2.3% | -7.5% | -18.0% | |
| Q1 2019 | -0.4% | -2.5% | -17.4% | |
| Q4 2018 | +6.2% | +11.3% | +15.6% | |
| Q3 2018 | -5.3% | -17.2% | -27.5% | |
| Q2 2018 | -8.0% | -7.5% | -7.5% | |
| Q1 2018 | -0.5% | +2.1% | -2.0% | |
| Q4 2017 | +3.1% | +7.5% | -7.8% | |
| Q3 2017 | -3.1% | -11.2% | +0.3% | |
| Q2 2017 | -12.6% | -13.5% | -17.9% | |
| Q1 2017 | +2.2% | +2.1% | -16.7% | |
| Q4 2016 | +10.9% | +6.4% | +5.9% | |
| Q3 2016 | +7.3% | -10.2% | +57.7% | |
| Q2 2016 | +1.2% | -3.7% | -6.1% | |
| Q1 2016 | -1.6% | — | — | |
| Q4 2015 | -0.4% | — | — | |
| Q3 2015 | -5.0% | — | — | |
| Q2 2015 | -10.6% | — | — | |
| Q1 2015 | -6.8% | — | — | |
| Q4 2014 | -5.4% | — | — | |
| Q3 2014 | +1.6% | — | — | |
| Q2 2014 | +9.5% | — | — | |
| Q1 2014 | — | — | — | |
| Q4 2013 | — | — | — | |
| Q3 2013 | — | — | — | |
| Q2 2013 | — | — | — | |
| Q1 2013 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro